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Background: All four dengue virus (DV) serotypes (D1V, D2V, D3V and D4V) can cause a series of disorders, ranging
from mild dengue fever (DF) to severe dengue hemorrhagic fever and dengue shock syndrome (DHF/DSS).
Previous studies have revealed that DV serotype-specific CD8+ T cells are involved in controlling DV infection.
Serotype cross-reactive CD8+ T-cells may contribute to the immunopathogenesis of DHF/DSS. The aim of the study
was to identify HLA-A*0201-binding peptides from four DV serotypes. We then examined their immunogenicity
in vivo and cross-reactivity within heterologous peptides.
Methods: D1V-derived candidate CD8+ T-cell epitopes were synthesized and evaluated for their affinity to the
HLA-A*0201 molecule. Variant peptides representing heterologous D2V, D3V, D4V serotypes were synthesized. The
immunogenicity of the high-affinity peptides were evaluated in HLA-A*0201 transgenic mice.
Results: Of the seven D1V-derived candidate epitopes [D1V-NS4a56–64(MLLALIAVL), D1V-C46–54(LVMAFMAFL),
D1V-NS4b562–570(LLATSIFKL), D1V-NS2a169–177(AMVLSIVSL), D1V-NS4a140–148(GLLFMILTV), D1V-NS2a144–152
(QLWAALLSL) and D1V-NS4b183–191(LLMRTTWAL)], three peptides [D1V-NS4a140–148, D1V-NS2a144–152 and D1V-
NS4b183–191] had a high affinity for HLA-A*0201 molecules. Moreover, their variant peptides for D2V, D3V and D4V
[D2V-NS4a140–148(AILTVVAAT), D3V-NS4a140-148(GILTLAAIV), D4V-NS4a140-148(TILTIIGLI), D2V-NS2a144–152(QLAVTIMAI),
D3V-NS2a144–152(QLWTALVSL), D4V-NS2a143–151(QVGTLALSL), D2V-NS4b182–190(LMMRTTWAL), D3V-NS4b182–190
(LLMRTSWAL) and D4V-NS4b179–187(LLMRTTWAF)] also had a high affinity for HLA-A*0201 molecules. Furthermore,
CD8+ T cells directed to these twelve peptides were induced in HLA-A*0201 transgenic mice following
immunization with these peptides. Additionally, cross-reactivity within four peptides (D1V-NS4b183–191,
D2V-NS4b182–190, D3V-NS4b182–190 and D4V-NS4b179–187) was observed.
Conclusions: Two novel serotype-specific HLA-A*0201-restricted CD8+ T-cell epitopes (NS4a140-148 and NS2a144–152)
and one cross-reactive HLA-A*0201-restricted CD8+ T-cell epitopes which is similar to a previously identified epitope
were identified in D1V-D4V. Combining prediction algorithms and HLA transgenic mice is an effective strategy to
identify HLA-restricted epitopes. Serotype-specific epitopes would be used to determine the protective role of
serotype-specific CD8+ T cells, while cross-reactive epitopes may provide assistance in exploring the role of serotype
cross-reactive CD8+ T cells in the immunopathogenesis of DHF/DSS.
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Dengue virus (DV) is a single-stranded positive-sense
RNA virus, of which there are four serotypes (D1V,
D2V, D3V and D4V). The viral genome encodes three
structural proteins (C, M and E) and seven non-
structural proteins (NS1, NS2a, NS2b, NS3, NS4a,
NS4b and NS5). DV is known to cause a spectrum of
illnesses, ranging from mild dengue fever (DF) to
severe dengue hemorrhagic fever and dengue shock
syndrome (DHF/DSS). Currently, DF and DHF/DSS
are major global public health problems. It is esti-
mated that 50,000,000–100,000,000 cases of DF and
250,000–500,000 cases of DHF/DSS occur every year
worldwide [1].
Despite several decades of research, there are no ef-
fective and safe DV vaccines. Previous studies have
shown that preexisting DV non-neutralizing antibodies
can enhance secondary heterologous DV serotype infec-
tions via antibody-dependent enhancement (ADE). ADE
may be the mechanism for development of DHF/DSS
during secondary heterologous DV serotype infections
[2-4]. It has been shown that infection with any one DV
serotype provides the body with protective immunity
against homologous DV serotypes, and with transient
cross-protection against heterologous DV serotypes [5].
The majority of studies have demonstrated that inter-
feron gamma (IFN-γ) plays an important role in the
clearance of DV following infection [6,7]. Subsequent
studies have indicated that DV-specific CD8+ T cells dis-
play lytic activity and/or produce IFN-γ [8,9]. A recent
study in mice confirmed that DV-specific CD8+ T cells
play a crucial role in controlling DV replication and in-
fection by secreting IFN-γ [10]. Thus, DV-specific CD8+
IFN-γ+ T cells may be critical for controlling DV infec-
tion. However, growing evidence suggests that a DV
serotype infection generates not only serotype-specific T
cells, but also serotype cross-reactive T cells which can
recognize multiple heterologous DV serotypes [9,11-15].
At present, it is accepted that DV serotype-specific T
cells provide protective immunity, while serotype cross-
reactive T cells induced by primary DV serotype infec-
tion are believed to mediate the immunopathogenesis of
DHF/DSS during secondary heterologous DV serotype
infection [8,16-18].
Because of the important role of serotype-specific
CD8+ T cells in limiting DV infection, a new strategy
for developing prophylactic and therapeutic CD8+ T-
cell epitope-based vaccines is needed. To avoid the
side effect of serotype cross-reactive CD8+ T cells, a
dengue vaccine must be a tetravalent vaccine that is
capable of providing protection against infection by
all four DV serotypes simultaneously [19]. Tetravalent
CD8+ T-cell epitope-based vaccines, which are mix-
tures of multiple heterologous variant CD8+ T-cellepitopes, could be promising candidate vaccines.
Although many DV-specific CD8+ T-cell epitopes
have been identified [9,11,12,17,20-23], the numbers
of HLA-A*0201-restricted epitopes are limited, despite
the high frequency of the HLA-A*0201 molecule in
most populations.
In the present study, we sought to screen the amino
acid sequences of D1V and used computational
algorithms to predict potential HLA-A*0201-restricted
CD8+ T-cell epitopes. Candidate CD8+ T-cell epitopes
and their variant peptides in D2V, D3V, D4V were tested
for their affinity to the HLA-A*0201 molecule, and for
their capacity to induce CD8+ T-cell responses in HLA-
A*0201 transgenic mice.Results
Affinity of candidate CD8+ T-cell epitopes for HLA-A*0201





BLAST results showed that these peptides are highly con-
served in more than 100 D1V strains (data not shown).
MHC-peptide complex stabilization assay results indicated
that three peptides (D1V-NS4a140-148, D1V-NS2a144–152
and D1V-NS4b183–191) showed peptide dose-dependent
HLA-A*0201-peptide binding [fluorescence index (FI)
exceeds 1 at a peptide concentration of 100 μg/ml], while
the other peptides demonstrated weak binding to HLA-
A*0201 (FI < 1; Table 1 and Figure 1). According to the
sequences for D1V-NS4a140-148, D1V-NS2a144–152 and
D1V-NS4b183–191, nine variant peptides derived from D2V,





(LLMRTTWAF)] were selected for synthesis. BLAST results
revealed that each of the nine peptides are highly conserved in
more than 80 given serotype strains (data not shown). The
variant sequences for D1V-NS4a140-148 and D1V-NS2a144–152
in D2V, D3V and D4V are highly variable. However, D2V-
NS4b182–190, D3V-NS4b182–190 and D4V-NS4b179–187 all dif-
fer from D1V-NS4b183–191 by a single amino acid. Regardless
of the amino acid variation, almost all nine variant peptides
bound to the HLA-A*0201 molecule with high affinity (for
D4V-NS2a143–151, the FI is 0.8). In total, twelve peptides
(D1V-NS4a140-148, D2V-NS4a140-148, D3V-NS4a140-148, D4V-
NS4a140-148, D1V-NS2a144–152, D2V-NS2a144–152, D3V-
NS2a144–152, D4V-NS2a143–151, D1V-NS4b183–191, D2V-
NS4b182–190, D3V-NS4b182–190 and D4V-NS4b179–187) had a
high affinity for HLA-A*0201 (Table 1 and Figure 1).
Table 1 Candidate epitopes and their affinity for HLA-A*0201 molecule of T2 cells
Peptides Serotypes Positiona Sequencesb Scorec FId ELISPOT
SFCs/1×105cells
ICS (%)e
CD8+IFN-γ+T cellsSYFPEITHI 1 μg 10 μg 100 μg
D1V-NS4a56-64 D1V NS4a (56-64) MLLALIAVL 29 0.05 0.05 0.08
D1V-C46-54 D1V C (46-54) LVMAFMAFL 20 0.01 0.02 0.02
D1V-NS4b562-570 D1V NS4b (562-570) LLATSIFKL 30 0.01 0.05 0.05
D1V-NS2a169-177 D1V NS2a (169-177) AMVLSIVSL 28 0.03 0.05 0.04
D1V-NS4a140-148 D1V NS4a (140-148) GLLFMILTV 30 0.28 0.85 4.5 58 ± 8 0.71 ± 0.11
D2V-NS4a140-148 D2V NS4a (140-148) AILTVVAAT 23 0.1 0.2 1.2 10 ± 3 0.12 ± 0.05
D3V-NS4a140-148 D3V NS4a (140-148) GILTLAAIV 24 0.1 0.15 4.05 37 ± 6 0.37 ± 0.08
D4V-NS4a140-148 D4V NS4a (140-148) TILTIIGLI 22 0.15 0.3 1.08 17 ± 5 0.21 ± 0.05
D1V-NS2a144-152 D1V NS2a (144-152) QLWAALLSL 28 0.05 0.22 1.12 36 ± 6 0.41 ± 0.07
D2V-NS2a144-152 D2V NS2a (144-152) QLAVTIMAI 25 0.24 0.39 3.85 21 ± 3 0.21 ± 0.05
D3V-NS2a144-152 D3V NS2a (144-152) QLWTALVSL 29 0.2 0.45 2.6 62 ± 9 0.79 ± 0.15
D4V-NS2a143-151 D4V NS2a (143-151) QVGTLALSL 18 0.22 0.2 0.8 12 ± 3 0.13 ± 0.06
D1V-NS4b183-191 D1V NS4b (183-191) LLMRTTWAL 26 0.29 0.4 1.95 42 ± 7 0.44 ± 0.09
D2V-NS4b182-190 D2V NS4b (182-190) LMMRTTWAL 24 0.58 3.42 4.8 37 ± 5 0.37 ± 0.09
D3V-NS4b182-190 D3V NS4b (182-190) LLMRTSWAL 24 0.22 0.65 3.6 24 ± 5 0.27 ± 0.07
D4V-NS4b179-187 D4V NS4b (179-187) LLMRTTWAF 16 0.2 0.59 4.4 22 ± 4 0.16 ± 0.06
a Position was determined according to the indicated DV serotype.
b Altered peptides representing heterologous DV serotypes. Bolded letters indicate the variant amino acid.
c Score predicted by online prediction algorithms SYFPEITHI.
d FI = [Mean fluorescence intensity(MFI) sample-MFI background]/MFI background.
e The proportion of CD8+IFN-γ+T cells in CD8+Tcells.
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transgenic mice
To evaluate the immunogenicity of high-affinity peptides,
splenocytes isolated from HLA-A*0201 transgenic mice
immunized with peptide were stimulated with a cognate
peptide. Enzyme-linked immunospot (ELISPOT) and
intracellular cytokine staining (ICS) assays were used to
detect homologous peptide-specific CD8+ T cells. ELI-
SPOT results revealed that immunized HLA-A*0201
transgenic mice had high levels of peptide-specific IFN-γ
spot-forming cells (SFCs) in splenocytes. All peptides
evoked an IFN-γ response in the ELISPOT assay that
exceeded 10 SFCs/1 × 105 splenocytes. D3V-NS2a144–152
immunization resulted in the highest frequency of IFN-γ-
secreting cells (62 ± 9 SFCs/1 × 105 splenocytes), while
D2V-NS4a140-148 immunization showed the lowest fre-
quency of IFN-γ-secreting cells (10 ± 3 SFCs/1 × 105 sple-
nocytes). As for D1V-NS4a140-148 and its variant peptides,
with the increase of FI, higher level of peptide-specific
IFN-γ-secreting cells was induced. In contrast, for D2V-
NS2a144-152, D1V-NS4b183-191 and their variant peptides,
the frequencies of peptide-specific IFN-γ-secreting cells
were not proportional to peptides’ FIs. For example, the
FIs of D1V-NS4a140-148 and D3V-NS4a140-148 were 4.5 and
4.05, respectively. These two peptides all induced higher
level of IFN-γ-secreting cells (58 ± 8 SFCs and 37 ± 6
SFCs, respectively). Although D2V-NS2a144-152 and D4V-
NS4b179-187 had higher FIs, they just induced median levelof IFN-γ-secreting cells (21±3 SFCs and 22±4 SFCs, re-
spectively). A summary of the individual peptides that
evoked responses in IFN-γ ELISPOT assays is provided in
Table 1 and Figures 2, 3, and 4. The ICS results defined
the phenotype of peptide-specific IFN-γ-secreting T cells,
and confirmed the human leukocyte antigen (HLA) re-
striction of these peptides. The high frequencies of CD8+
IFN-γ+ T cells were detected in splenocytes after being sti-
mulated with cognate peptide. The highest percentage of
CD8+ IFN-γ+ T cells was specific for D3V-NS2a144–152
(0.79 ± 0.15%). The lowest percentage of CD8+ IFN-γ+ T
cells was directed against D2V-NS4a140-148 (0.12 ± 0.05%;
Table 1, Figures 5, 6, and 7). The ELISPOT results were
consistent with the ICS results. Additionally, these pep-
tides were tested in an IFN-γ ELISPOT assay and an ICS
assay using splenocytes from mock-immunized HLA-
A*0201 transgenic mice. They were also tested using sple-
nocytes from peptide-immunized C57BL/6 mice. Signifi-
cant responses were not observed in either of these
situations (data not shown).
Cross-reactivity of peptide-specific CD8+ T cells
To further explore the cross-reactivity between a given
peptide and its variants, we examined the ability of
peptide-specific CD8+ T cells to recognize a heterol-
ogous peptide variant representing another DV serotype.
Splenocytes from D1V-NS4b183–191-immunized mice
exhibited marked cross-reactivity towards D2V-NS4b182–
Figure 1 The affinity of candidate epitopes for HLA-A*0201 molecules. T2 cells were incubated in RPMI 1640 medium lacking peptides (red)
or containing low peptide (1 μg/ml) (green) or intermediate peptide (10 μg/ml) (purple) or high peptide (100 μg/ml) (blue) for 15 h and stained
with FITC-conjugated anti-HLA-A*0201 antibody. Then, mean fluorescence intensity (MFI) was measured using flow cytometry.
Duan et al. Virology Journal 2012, 9:259 Page 4 of 12
http://www.virologyj.com/content/9/1/259190, D3V-NS4b182–190 and D4V-NS4b179–187. Similar data
were obtained for D2V-NS4b182–190, D3V-NS4b182–190
and D4V-NS4b179–187 (Figures 4 and 7). The proportion
of CD8+ IFN-γ+ T cells responding to all four peptides
ranged from 0.16–0.44%. For D1V-NS4b183–191 and
D2V-NS4b182–190, the same variant peptides induced the
highest CD8+ T-cell response in all peptide-immunized
mice. In total, higher responses to homologous peptideswere more common than responses to variant peptides.
For the remaining eight peptides, stimulation of spleno-
cytes with their corresponding variants did not give rise
to CD8+ IFN-γ+ T cells.
Discussion
Both our previous reports and other studies indicate
that combining prediction algorithms with several
Figure 2 Magnitude of the ELISPOT response to D1V-NS4a140-148 and heterologous peptides in HLA-A*0201 transgenic mice
immunized with peptides. Splenocytes were isolated from the peptide-immunized mice and were stimulated in vitro with cognate peptide or
heterologous peptide. The numbers of IFN-γ SFCs/1×105 splenocytes were detected using ELISPOT assay. *Indicating the positive response to a
peptide.
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cation of immunogenic T-cell epitopes [21,24]. It is
established that HLA-A*0201 is the major haplotype in
most of the world population, irrespective of gender
and race [25]. Therefore, HLA-A*0201-restricted CD8+
T-cell epitopes would likely have broad population
coverage.In the present study, seven D1V-derived potential HLA-
A*0201-restricted candidate epitopes were evaluated for
their binding capacity to HLA-A*0201. Three peptides
were identified as high-affinity peptides. Almost all var-
iants of these three peptides in D2V, D3V, D4V have a
high affinity for HLA-A*0201. In total, twelve peptides
demonstrated a high affinity for HLA-A*0201.
Figure 3 Magnitude of the ELISPOT response to D1V-NS2a144-152 and heterologous peptides in HLA-A*0201 transgenic mice
immunized with peptides. Splenocytes were isolated from the peptide-immunized mice and were stimulated in vitro with cognate peptide or
heterologous peptide. The numbers of IFN-γ SFCs/1×105 splenocytes were detected using ELISPOT assay. *Indicating the positive response to a
peptide.
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amino acid residue at position 2, and an L, I or V residue at
position 9. Among sixteen candidate epitopes described here,
D1V-NS4a140-148, D3V-NS4a140-148, D4V-NS4a140-148, D1V-
NS2a144–152, D2V-NS2a144–152, D3V-NS2a144–152, D1V-
NS4b183–191 and D3V-NS4b182–190 followed this classicpattern. They also showed a high affinity for HLA-A*0201
(FI > 1). D1V-NS4a56–64 and D1V-NS4b562–570 had a low-
affinity for HLA-A*0201, even though they shared these
classic residues at the relevant positions (FI < 0.5). In
contrast, although neither D2V-NS4b182–190 (position 2
is M) nor D4V-NS4b179–187 (position 9 is F) conformed
Figure 4 Magnitude of the ELISPOT response to D1V-NS4b183-191 and heterologous peptides in HLA-A*0201 transgenic mice
immunized with peptides. Splenocytes were isolated from the peptide-immunized mice and were stimulated in vitro with cognate peptide or
heterologous peptide. The numbers of IFN-γ SFCs/1×105 splenocytes were detected using ELISPOT assay. *Indicating the positive response to a
peptide.
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for HLA-A*0201 (FI > 4). A possible explanation for
these phenomena may be that amino acids in other posi-
tions drastically affect binding avidity.
To further evaluate the immunogenicity and HLA allele
restriction of these high-affinity peptides, we assessed
whether these twelve peptides could elicit CD8+ T-cellresponses in HLA-A*0201 transgenic mice. Although
these twelve peptides had different affinities for HLA-
A*0201, they all triggered peptide-specific CD8+ T cell
responses. The magnitude of responses to individual pep-
tides ranged from 10–62 SFCs/1×105 splenocytes. Our
results appear to correspond with those seen in other
studies. The frequencies of CD8+ IFN-γ+ T cells that
Figure 5 Detection of peptide-specific CD8+ IFN-γ+ T cells in HLA-A*0201 transgenic mice immunized with D1V-NS4a140-148 or
heterologous peptides. Splenocytes were isolated from the peptide-immunized mice and were stimulated in vitro with cognate peptide or
heterologous peptide. The percentages of CD8+ IFN-γ+ T cells in CD8+ T cells were measured using ICS assay. *Indicating the positive response to
a peptide.
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A*0201 transgenic mice (0.12–0.79% CD8+ IFN-γ+ T cells
of all CD3+ CD8+ T cells) is in line with frequencies
detected in humanized mice (0.1–2.8% of all CD3+ CD8+
T cells) [26,27], and in human peripheral blood mono-
nuclear cells (PBMCs) from DV immune donors (0.1–
0.68% of all CD3+ CD8+ T cells) [12,21]. These peptides
did not induce significant CD8+ T-cell responses in mock-
immunized HLA-A*0201 transgenic or C57BL/6 mice
(data not shown). These data further confirmed that these
twelve peptides were recognized by HLA-A*0201.
Additionally, a high frequency of D1V-NS4a140-148 and
D3V-NS2a144–152-specific CD8
+ T cells in peptide-
immunized HLA-A*0201 transgenic mice suggests that
these peptides might be the immunodominant HLA-
A*0201-restricted epitopes. In recent years, research stud-
ies have revealed many DV-specific CD8+ T-cell epitopes.These are mostly located in E, NS3, NS4a, NS4b, NS5 and
restricted by HLA-A2, A11, A24, B7, B55, B65
[9,11,12,17,20-23]. Lund et al [22] and Weiskopf et al [23]
used HLA-A*0201 transgenic mice and identified several
D1V- and D2V-specific HLA-A*0201-retricted epitopes,
respectively. Weiskopf et al [23] also found that most of
the epitopes identified in the murine system are also
recognized by PBMCs from DV-exposed human donors.
In the present study, based on a similar strategy, we iden-
tified NS2a-, NS4a- and NS4b-derived HLA-A*0201-
restricted CD8+ T-cell epitopes from D1V–D4V. Our
results suggest that NS2a, NS4a and NS4b are involved in
cellular immunity during DV infection.
Previous studies have shown that DV-specific CD8+ T cells
from DV-immunized or infected subjects exhibited a cross-
reactive response to variant peptides representing a heterol-
ogous serotype [9,12,15]. In this study, for D1V-NS4b183–191
Figure 6 Detection of peptide-specific CD8+ IFN-γ+ T cells in HLA-A*0201 transgenic mice immunized with D1V-NS2a144-152 or
heterologous peptides. Splenocytes were isolated from peptide-immunized mice and were stimulated in vitro with cognate peptide or
heterologous peptide. The percentages of CD8+ IFN-γ+ T cells in CD8+ T cells were measured using ICS assay. *Indicating the positive response to
a peptide.
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and D4V-NS4b179–187) each elicited peptide-specific CD8
+ T
cells, which exhibited cross-reactivity towards its variants.
These data suggest that D1V infection followed by D2V,
D3V or D4V infection (or vice versa) would trigger the ac-
tivation of cross-reactive IFN-γ-producing CD8+ T cells.
Cross-reactivity may be explained by the primary structure of
these variants: D2V-NS4b182–190(LMMRTTWAL), D3V-
NS4b182–190(LLMRTSWAL), and D4V-NS4b179–187(LLM
RTTWAF). Each of these differs from D1V-NS4b183–191
(LLMRTTWAL) by a single amino acid. D1V-NS4b183–191
and D3V-NS4b182–190 shared the same anchors at positions 2
(L) and 9 (L). These are critical positions for HLA recognition
and T-cell activation. These two peptides have only one
amino acid change at position 6 (T→S). For D2V-NS4b182–190 and D4V-NS4b179–187, the residues at positions 2 or 9 dif-
fer from D1V-NS4b183–191 and D3V-NS4b182–190. We believe
that the amino acid change will not affect functional avidity
(IFN-γ secretion). In a recent study using HLA-A*0201-posi-
tive D1V/D2V/D3V-immune donors, Bashyam et al [12]
reported four cross-reactive epitopes (D1V-ILLMRTTWA,
D2V-VLLMRTTWA, D3V-LLLMRTSWA and D4V-LLL
MRTTWA). In comparison, we found those epitopes along
with the ones reported in this paper to share 7 or 8 amino
acids. We are confident that the shared amino acid sequences
may determine HLA-A*0201 restriction and Tcell recognition.
Conclusions
In summary, based on the amino acid sequences of D1V-
D4V, we identified two novel serotype-specific HLA-A*0201-
Figure 7 Detection of peptide-specific CD8+ IFN-γ+ T cells in HLA-A*0201 transgenic mice immunized with D1V-NS2a183-191 or
heterologous peptides. Splenocytes were isolated from the peptide-immunized mice and were stimulated in vitro with cognate peptide or
heterologous peptide. The percentages of CD8+ IFN-γ+ T cells in CD8+ T cells were measured using ICS assay. *Indicating the positive response to
a peptide.
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and one cross-reactive HLA-A*0201-restricted CD8+ T-cell
epitopes which is similar to a previously identified epitope. In
the following study, we would explore whether these
peptide could be recognized by PBMCs from human
donors infected with DV. Our results show that using
a combination of prediction algorithms and HLA
transgenic mice is effective for identifying HLA-
restricted epitopes. In general, the antiviral activity of
CD8+ T cells is mediated by the production of cyto-
kines, particularly IFN-γ. Further studies will be
needed to determine the protective role of these
serotype-specific epitopes. D1V-NS4b183–191, D2V-
NS4b182–190, D3V-NS4b182–190 and D4V-NS4b179–187
cross-reacted with each other, therefore further evaluation
of the functional phenotype of serotype cross-reactive
CD8+ T cells induced by these peptides would reveal theexact mechanism of T cell-mediated immunopathogenesis
during secondary heterologous DV serotype infection.
Methods
Epitope prediction and peptide synthesis
Based on the amino acid sequence of D1V (Hawaii
strain; GenBank Accession No: ACF49259), the epi-
tope prediction algorithms SYFPEITHI with PAProc
(http://www.syfpeithi.de; http://www.paproc.de) were
applied to predict HLA-A*0201-restricted CD8+ T-cell
epitopes. The following criteria were used to select
candidate CD8+ T-cell epitopes. First, the candidate
epitope should be a nonapeptide that has a high pre-
dictive score and a protease cleavage site (C terminus).
Second, the sequence of the candidate epitope should be
highly conserved in most D1V strains. If a candidate epi-
tope has a high affinity for HLA-A*0201 as confirmed by
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peptides in D2V (NGC strain; AAC59275), D3V (H87
strain; AAA99437) and D4V (H241 strain; AAX48017)
would be selected and synthesized. All peptides were
synthesized at > 90% purity by ChinaPeptides Co., Ltd
(Shanghai, China).
Cells and mice
The transporter associated with antigen processing
(TAP)-deficient T2 cell line was purchased from ATCC
(Manassas, VA, USA). Female C57BL/6-Transgenic
(HLA-A2.1)1Enge/J mice (HLA-A*0201 transgenic mice;
6–8 weeks) were purchased from the Jackson Laboratory
(Bar Harbor, ME, USA). Female C57BL/6 mice (6–8
weeks) were provided by the Laboratory Animal Center
of Wenzhou Medical College.
MHC-peptide complex stabilization assay
The ability of peptides to stabilize MHC molecules on
the surface of T2 cells was measured as described previ-
ously [21]. T2 cells (2 × 105 cells/0.5 ml) were incubated
in serum-free RPMI 1640 medium in the presence of
different concentrations of peptide (1, 10, 100 μg/ml)
for 1 h at 37°C/5% CO2 incubator. Cells were then incu-
bated at 26°C for 12 h, and then returned to 37°C for a
3 h incubation. Finally, T2 cells were stained with FITC-
conjugated anti-HLA-A*0201 antibody (BD Pharmin-
gen, USA) for 40 min at 4°C. T2 cells incubated in
serum-free RPMI 1640 medium without peptides served
as a negative control (background). Mean fluorescence
intensity (MFI) of T2 cells was recorded with a FACS
Calibur flow cytometer (BD bioscience, USA), and
results expressed as fluorescence index (FI). The follow-
ing formula was used to calculate the FI.
FI ¼ MFI sampleMFI background
MFI background
Immunization of HLA-A*0201 transgenic mice
HLA-A*0201 transgenic mice were subdivided into 12
groups (4 mice/group). Mice were inoculated subcutane-
ously with high-affinity peptide (50 μg/mouse) emulsified in
Freund’s complete adjuvant. One week later, mice were
immunized with the same peptide emulsified in Freund’s
incomplete adjuvant. Mice were boosted three more times
at weekly intervals. Mock-immunized (adjuvant alone)
HLA-A*0201 transgenic mice and peptide-immunized
C57BL/6 mice served as controls. One week after the final
immunization, all mice were sacrificed and splenocytes
extracted. ELISPOT and ICS assays were conducted to de-
tect the frequencies of peptide-specific IFN-γ-producing
cells. All animal were performed following the Institutional
Animal Care and Use Committee-approved protocols.IFN-γ ELISPOT assays
Splenocytes were resuspended to a final concentration of
1 × 106 cells/ml in RPMI 1640 medium supplemented
with 10% fetal bovine serum (FBS). ELISPOT assays were
performed in pre-coated 96-well plates (U-CyTech Com-
pany, Netherlands). Splenocytes were seeded at 1 × 105
cells/well and exposed to either cognate or heterologous
peptide at a final concentration of 10 μg/ml. Negative con-
trol wells contained splenocytes but no peptide. Positive
control wells included cells plus phytohemagglutinin
(PHA) at a final concentration of 10 μg/ml. All tests were
carried out in duplicate wells, with plates incubated for
24 h at 37°C/5% CO2. Plates were washed and then incu-
bated with biotinylated anti-mouse IFN-γ for 1 h at 37°C.
After washing, plates were labeled with streptavidin-
horseradish peroxidase, and developed using fresh ACE
solution as a substrate. IFN-γ spots were counted using an
ELISPOT reader (Beijing SageCreation Science Co. Ltd,
Beijing, China). Peptide-specific T-cell frequency was
expressed as SFCs/1 × 105 splenocytes. Background
spots (negative control wells) were subtracted from
test wells. A positive response to a peptide was
defined as having > 5 SFCs/1 × 105 splenocytes after
subtraction of the background.ICS assays
Splenocytes were cultured with either cognate peptide
(10 μg/ml) or heterologous peptide (10 μg/ml) in a 1.5 ml
microcentrifuge tube for 6 h at 37°C/5% CO2. Negative
controls did not receive any peptide stimulation. During
the last 5 h, brefeldin A (10 μg/ml) was added to each
tube. After a 6 h incubation, cells were washed and then
stained with APC-conjugated anti-mouse CD3 and FITC-
conjugated anti-mouse CD8 antibodies (eBioscience com-
pany, USA) for 40 min at 4°C. Cells were then washed and
fixed with 4% paraformaldehyde for 20 min at 4°C, per-
meabilized using 0.5% saponin for 10 min at 4ºC, and
stained with PE-conjugated anti-mouse IFN-γ antibody
(eBioscience company, USA) for 40 min at 4°C. A FACS
Calibur flow cytometer (BD Bioscience, USA) was used to
analyze labeled cells. CD3+ CD8+ T cells were gated and
the proportion of IFN-γ-producing CD8+ T cells (CD8+
IFN-γ+ T cells) as a subset of all CD8+ T cells were
determined.Statistical analysis
Data are expressed as mean value ± standard deviation
(SD). The Student’s t-test was used to test statistical
significance. P values of < 0.05 were considered statisti-
cally significant.
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